Jennifer Kim
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
40
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jennifer Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Reiterates: Overweight | n/a | $68.32 | - | 6 | Jun 20, 2024 | |
| FBIO Fortress Biotech | Reiterates: Overweight | n/a | $1.90 | - | 4 | Jun 20, 2024 | |
| EYPT EyePoint Pharmaceuticals | Reiterates: Overweight | n/a | $12.06 | - | 6 | Jun 20, 2024 | |
| BLTE Belite Bio | Reiterates: Overweight | n/a | $69.90 | - | 3 | Jun 20, 2024 | |
| ALLK Allakos | Reiterates: Neutral | n/a | $1.27 | - | 4 | Jun 20, 2024 | |
| PGEN Precigen | Reiterates: Overweight | n/a | $0.82 | - | 3 | May 15, 2024 | |
| PSTX Poseida Therapeutics | Reiterates: Overweight | $14 | $2.47 | +466.80% | 2 | Oct 10, 2023 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $0.95 | +110.68% | 2 | Aug 31, 2023 | |
| CKPT Checkpoint Therapeutics | Maintains: Overweight | $19 → $14 | $3.51 | +298.86% | 4 | Aug 15, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $6.08 | +442.76% | 2 | Jul 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $3.73 | +20.64% | 2 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $100 | $1.94 | +5,061.29% | 2 | May 17, 2022 |
Insmed
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $68.32
Upside: -
Fortress Biotech
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.90
Upside: -
EyePoint Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.06
Upside: -
Belite Bio
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $69.90
Upside: -
Allakos
Jun 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.27
Upside: -
Precigen
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.82
Upside: -
Poseida Therapeutics
Oct 10, 2023
Reiterates: Overweight
Price Target: $14
Current: $2.47
Upside: +466.80%
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $0.95
Upside: +110.68%
Checkpoint Therapeutics
Aug 15, 2023
Maintains: Overweight
Price Target: $19 → $14
Current: $3.51
Upside: +298.86%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $6.08
Upside: +442.76%
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $3.73
Upside: +20.64%
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $1.94
Upside: +5,061.29%